Clinical references, built for prescribers.
Evidence-graded peptide references, protocol summaries, and regulatory tracking — the same independent, source-cited material we publish, organized for clinical use.
Editorial independence We take no payment for coverage, placement or rankings, and we publish corrections. Editorial policy
References, protocols, and the regulatory picture.
Every peptide we cover has a source-cited reference page — mechanism, the human evidence (and where it runs out), dosing as reported in the literature, safety, and regulatory status. The sections below organize that material for clinical reference, alongside the compounding and regulatory intelligence prescribers ask about most.
Peptide reference library
Source-cited pages on each peptide — mechanism, evidence tier, dosing, safety, legal status.
Open the library →SourcingCompounding pharmacies
How to evaluate accredited 503A/503B compounders, side by side.
Compare pharmacies →RegulatoryRegulatory tracking
503A/503B changes and compounding policy, with dates.
See updates →Protocol summaries
Standardized, prescriber-facing protocol packs.
Coming soonWhitepapers
Independent field reports — in production, not yet available.
See what's coming →PrimerHow peptides are prescribed
Rx pathways, DEA scheduling, telehealth, and insurance.
Read the primer →Start here.
The pages prescribers reach for most, in one place:
- GLP-1 receptor agonists — the class explainer, with semaglutide, tirzepatide, and retatrutide.
- Recovery: BPC-157 and TB-500 — mechanism, human evidence, and where it runs out.
- How peptides are prescribed — Rx pathways, DEA scheduling, telehealth, and insurance.
- FDA-approved peptide drugs — what's approved, what's compoundable, and what's neither.
- Is peptide therapy safe? — the substance / sourcing / oversight framework.
- Compounding pharmacies — how to evaluate a 503A/503B compounder.
- Our methodology — how we grade evidence and source every claim.